Mandadapu, Sivakoteswara RaoWeerawarna, Pathum M.Prior, Allan M.Uy, Roxanne Adeline Z.Aravapalli, SridharAlliston, Kevin R.Lushington, Gerald H.Kim, YunjeongHua, Duy H.Chang, Kyeong-OkGroutas, William C.2013-09-062013-09-062013-07-01http://hdl.handle.net/2097/16411The design, synthesis, and in vitro evaluation of the first macrocyclic inhibitor of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus are reported. The in vitro inhibitory activity (50% effective concentration) of the macrocyclic inhibitor toward enterovirus 3C protease (CVB3 Nancy strain), and coronavirus (SARS-CoV) and norovirus 3C-like proteases, was determined to be 1.8, 15.5 and 5.1 μM, respectively.en-USThis Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).ProteasesPicornavirusNorovirusCoronavirusMacrocyclic inhibitorsArticle (author version)